[6-fluoro-2-methyl-3-(4-oxazol-2-ylphenylsulfanyl)indolizin-1-yl]acetic acid | 1036713-64-0

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: [6-fluoro-2-methyl-3-(4-oxazol-2-ylphenylsulfanyl)indolizin-1-yl]acetic acid
• 英文别名: 2-[6-Fluoro-2-methyl-3-[4-(1,3-oxazol-2-yl)phenyl]sulfanylindolizin-1-yl]acetic acid
• CAS: 1036713-64-0
• 化学式: C₂₀H₁₅FN₂O₃S
• 分子量: 382.415
• InChiKey: WFZXVUIMFNVAFX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  93
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Indolizineacetic Acids and Their Therapeutic Use as Ligands of the CRTH2 Receptor
  申请人：Hynd George

  公开号：US20100093751A1

  公开（公告）日：2010-04-15

  Compounds of formula (I) are CRTH2 ligands, useful in the treatment of, inter alia, respiratory diseases: wherein R 1 is fluoro, chloro, cyano or trifluoromethyl; R 2 is hydrogen, fluoro or chloro; R 3 is hydrogen, fluoro, chloro or trifluoromethyl; X is —CH 2 —, —S—, —S(═O)— or —S(═O) 2 —; one of Y and Y 1 is hydrogen and the other is —C(═O)R 4 , or —S(═O) 2 R 4 , or —CR 5 R 6 OR 7 or a heterocyclic group selected from furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, furazanyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,4-thiadiazolyl, tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,2,4-triazinyl and 1,3,5-triazinyl any of which may be optionally substituted; R 4 is an optionally substituted cyclic amino group having 5, 6 or 7 ring atoms which is linked to the carbonyl or sulfonyl through a ring nitrogen; R 5 and R 6 are independently hydrogen, (C 1 C 3 )alkyl, cyclopropyl, or R 5 and R 6 taken together with the carbon atom to which they are attached form a 3-6 membered cycloalkyl ring; and R 7 is optionally substituted (C 1 -C 6 )alkyl or (C 3 -C 6 )cycloalkyl,

  公式（I）的化合物是CRTH2配体，可用于治疗呼吸系统疾病，其中R1为氟、氯、氰或三氟甲基；R2为氢、氟或氯；R3为氢、氟、氯或三氟甲基；X为-CH2-、-S-、-S（═O）-或-S（═O）2-；Y和Y1中的一个为氢，另一个为-C（═O）R4、-S（═O）2R4、-CR5R6OR7或从呋喃基、噻吩基、吡咯基、噁唑基、噻唑基、咪唑基、吡唑基、异噁唑基、异噻唑基、1,2,3-噁二唑基、1,2,4-噁二唑基、1,3,4-噁二唑基、1,2,5-噁二唑基、呋嗪基、1,2,3-三唑基、1,2,4-三唑基、1,2,3-噻二唑基、1,2,5-噻二唑基、1,3,4-噻二唑基、1,2,4-噻二唑基、四唑基、吡啶基、吡嗪基、嘧啶基、吡咯嗪基、1,2,4-三嗪基和1,3,5-三嗪基中选择的杂环基，其中任何一个均可选择性地被取代；R4是一个具有5、6或7个环原子的可选择性取代的环氨基基团，通过一个环氮原子与羰基或磺酰基相连；R5和R6独立地为氢、（C1-C3）烷基、环丙基，或R5和R6与它们附着的碳原子一起形成一个3-6个成员的环烷基环；R7是可选择性取代的（C1-C6）烷基或（C3-C6）环烷基。
• INDOLIZINEACETIC ACIDS AND THEIR THERAPEUTIC USE AS LIGANDS OF THE CRTH2 RECEPTOR
  申请人：Argenta Discovery Limited

  公开号：EP2121686A1

  公开（公告）日：2009-11-25
• [EN] INDOLIZINEACETIC ACIDS AND THEIR THERAPEUTIC USE AS LIGANDS OF THE CRTH2 RECEPTOR<br/>[FR] INDOLIZINEACÉTIQUE ACIDES ET LEUR UTILISATION THÉRAPEUTIQUE COMME LIGANDS DU RÉCEPTEUR CRTH2
  申请人：ARGENTA DISCOVERY LTD

  公开号：WO2008078069A1

  公开（公告）日：2008-07-03

  [EN] Compounds of formula (I) are CRTH2 ligands, useful in the treatment of, inter alia, respiratory diseases: wherein R¹ is fluoro, chloro, cyano or trifluoromethyl; R² is hydrogen, fluoro or chloro; R³ is hydrogen, fluoro, chloro or trifluoromethyl; X is -CH₂-, -S-, -S(=O)- or -S(=O)₂-; one of Y and Y¹ is hydrogen and the other is -C(=O)R⁴, or -S(=O)₂R⁴, or -CR⁵R⁶OR⁷ or a heterocyclic group selected from furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, furazanyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3- thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,4-thiadiazolyl, tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,2,4-triazinyl and 1,3,5-triazinyl any of which may be optionally substituted; R⁴ is an optionally substituted cyclic amino group having 5, 6 or 7 ring atoms which is linked to the carbonyl or sulfonyl through a ring nitrogen; R⁵ and R⁶ are independently hydrogen, (C₁C₃)alkyl, cyclopropyl, or R⁵ and R⁶ taken together with the carbon atom to which they are attached form a 3-6 membered cycloalkyl ring; and R⁷ is optionally substituted (C₁-C₆)alkyl or (C₃- C₆)cycloalkyl,
  [FR] L'invention concerne des composés de la formule (I) qui sont des ligands de CRTH2, utiles dans le traitement, entre autres, de maladies respiratoires, où R¹ est fluoro, chloro, cyano ou trifluorométhyle; R² est hydrogène, fluoro ou chloro; R³ est hydrogène, fluoro, chloro ou trifluorométhyle; X est -CH₂-, -S-, -S(=O)- ou -S(=O)₂-; de Y et Y¹, l'un est hydrogène et l'autre est -C(=O)R⁴, ou -S(=O)₂R⁴, ou -CR⁵R⁶OR⁷ ou un groupe hétérocyclique choisi entre furanyle, thienyle, pyrrolyle, oxazolyle, thiazolyle, imidazolyle, pyrazolyle, isoxazolyle, isothiazolyle, 1,2,3-oxadiazolyle, 1,2,4-oxadiazolyle, 1,3,4-oxadiazolyle, 1,2,5-oxadiazolyle, furazanyle, 1,2,3-triazolyle, 1,2,4-triazolyle, 1,2,3- thiadiazolyle, 1,2,5-thiadiazolyle, 1,3,4-thiadiazolyle, 1,2,4-thiadiazolyle, tétrazolyle, pyridinyle, pyridazinyle, pyrimidinyle, pyrazinyle, 1,2,4-triazinyle et 1,3,5-triazinyle, dont n'importe lequel peut être facultativement substitué; R⁴ est un groupe amino cyclique facultativement substitué renfermant 5, 6 ou 7 atomes cycliques, qui est lié au carbonyle ou au sulfonyle via un azote cyclique; R⁵ et R⁶ sont indépendamment hydrogène, (C₁C₃)alkyle, cyclopropyle, ou R⁵ et R⁶ pris ensemble avec l'atome de carbone auquel ils sont attachés forment un noyau cycloalkyle de 3 à 6 chaînons; et R⁷ est un (C₁-C₆)alkyle ou un (C₃- C₆)cycloalkyle facultativement substitué.